$DREAMMing of a Better Tomorrow: Belantamab-Based Triplet Therapy for Relapsed/Refractory Multiple Myeloma$

DREAMMing of a Better Tomorrow: Belantamab-Based Triplet Therapy for Relapsed/Refractory Multiple Myeloma

Update: 2024-12-21

Description

In this episode, Contributing Editor Ajai Chari, MD, a professor of clinical medicine and director of the myeloma program at the University of California San Francisco, talks with Meletios Dimopoulos, MD, a professor and chair of the Department of Clinical Therapeutics at the National and Kopodistrian University of Athens School of Medicine in Athens, Greece. They talk about a recent paper co-authored by Dr. Dimopoulos: “Belantamab Mafodotin, Pomalidomide (PA), and Dexamethasone in Multiple Myeloma.”

Comments

Top Podcasts

The Best New Comedy Podcast Right Now – June 2024 The Best News Podcast Right Now – June 2024 The Best New Business Podcast Right Now – June 2024 The Best New Sports Podcast Right Now – June 2024 The Best New True Crime Podcast Right Now – June 2024 The Best New Joe Rogan Experience Podcast Right Now – June 20 The Best New Dan Bongino Show Podcast Right Now – June 20 The Best New Mark Levin Podcast – June 2024

In Channel

$DREAMMing of a Better Tomorrow: Belantamab-Based Triplet Therapy for Relapsed/Refractory Multiple Myeloma$

DREAMMing of a Better Tomorrow: Belantamab-Based Triplet Therapy for Relapsed/Refractory Multiple Myeloma

2024-12-2118:56

Haploidentical Stem Cell Transplantation Is an Acceptable Transformative Therapy for Young Adults With Sickle Cell Disease

2024-11-2723:43

Enhancing Risk Stratification for Pediatric B-Cell Acute Lymphoblastic Leukemia: No Longer a ‘PI’ in the Sky Idea?

2024-10-1118:11

A Leap of Faith? Elimination of Autologous Stem Cell Transplantation for Patients With Mantle Cell Lymphoma in First Remission

2024-09-1621:39

Anticoagulation Stewardship

2024-08-2925:56

Blood Global Hematology Editor-in-Chief Shares Vision

2024-07-1716:52

One on One With Dr. Fred Appelbaum

2024-06-2626:25

Genetic Switch System Suggests Targeting of Mutant JAK2 Reverses Myeloproliferative Neoplasms

2024-06-2123:49

Venous Thromboembolism Risk Markers and Discontinuing Combined Hormonal Contraceptives

2024-05-0725:41

Growing the Next Generation of Hematologists

2024-04-1520:14

Women in Hematology

2024-03-2626:39

Four Is Better Than Three: Will We Finally Agree?

2024-03-1823:18

Toward Equity in Access for ALL

2024-01-3026:42

The Brilliant Success of Blinatumomab for Babies With Acute Lymphoblastic Leukemia

2023-11-2916:13

Editors-in-Chief of Two New ASH Journals Share Their Visions

2023-10-2025:16

ASH’s Minority Recruitment Initiative Mentorship Program Offers a Win for All

2023-09-1814:20

Results From the Blood and Marrow Transplant Trials Network: How Should We Prevent Graft-versus-host Disease in 2023?

2023-09-0128:05

Genetic Background Influences the Growth of CHIP Clones Within the Bone Marrow, With Drs. Robert Hasserjian and Siddhartha Jaiswal

2023-07-0727:12

Drawing New Blood Into Hematology

2023-06-1631:39

Anticoagulation and Abnormal Uterine Bleeding: Acknowledging Calls to Action

2023-05-1825:13

00:00

1.0x

$DREAMMing of a Better Tomorrow: Belantamab-Based Triplet Therapy for Relapsed/Refractory Multiple Myeloma$

DREAMMing of a Better Tomorrow: Belantamab-Based Triplet Therapy for Relapsed/Refractory Multiple Myeloma

#box-pro-ellipsis-173490898689696{-webkit-line-clamp:2;}DREAMMing of a Better Tomorrow: Belantamab-Based Triplet Therapy for Relapsed/Refractory Multiple Myeloma

DREAMMing of a Better Tomorrow: Belantamab-Based Triplet Therapy for Relapsed/Refractory Multiple Myeloma

The Hematologist

DREAMMing of a Better Tomorrow: Belantamab-Based Triplet Therapy for Relapsed/Refractory Multiple Myeloma